Biotech Values

[DewDiligence]

From the WSJ piece you posted on HCV drugs:

Other new drugs are in the pipeline from AbbVie, Bristol-Myers Squibb Co. and Merck & Co. but they aren't expected to start winning approvals until next year.

Actually, ABBV has guided investors to expect approval and launch of ABBV/ENTA’s 3-DAA regimen in late 2014 (#msg-96615816); this guidance assumes that the NDA will be submitted during April insofar as the FDA timeline for priority review of a BTD application is 8 months.